Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
PureTech Health Q4 2025 Earnings Call - Celea Financing Nears Completion While Gallop Prioritizes MDS Indication
PureTech Health is tightening its operational focus and streamlining its structure to accelerate value creation across its hub-and-spoke biotech portfolio. The company announced plans to voluntarily d...
- PureTech Health plans to voluntarily delist from the Nasdaq to simplify its structure and reduce administrative costs, while maintaining its primary listing on the London Stock Exchange.
- The company’s refined strategy involves launching founded entities earlier in the development cycle to improve capital efficiency and create a greater number of externally capitalized biotechs.
- Celea Therapeutics’ fundraising for its phase III SURPASS-IPF trial is substantially complete, with a target close in early Q3 2026 to support the upcoming trial.
- +9 more takeaways
Brookfield Infrastructure Partners 2026 Q1 Earnings Call - Record FFO Driven by Data Segment Surge and Capital Recycling Momentum
Brookfield Infrastructure Partners delivered a record first quarter 2026, generating $709 million in funds from operations and achieving 10% year-over-year growth. The results were anchored by a 46% s...
- Brookfield Infrastructure Partners reported record first quarter 2026 FFO of $709 million, representing a 10% year-over-year increase.
- The data segment experienced a 46% surge in FFO to $149 million, driven by the U.S. bulk fiber network acquisition and commissioning of over 200 megawatts of data centers.
- Capital recycling efforts yielded $1 billion in secured proceeds, including sales of stabilized data centers, Brazilian transmission assets, and a secondary sale of a North American gas storage interest.
- +7 more takeaways
Teradyne Q1 2026 Earnings Call - Record AI-Driven Revenue Hits $1.3B With Lumpy Growth Ahead
Teradyne delivered a record first quarter in 2026, with revenue of $1.282 billion and non-GAAP EPS of $2.56, surpassing its previous high-water mark from the 2021 mobile peak. AI-related demand now ac...
- Teradyne reported record Q1 2026 revenue of $1.282 billion and non-GAAP EPS of $2.56, beating the high end of guidance and surpassing its previous record from Q2 2021.
- AI-related demand accounted for nearly 70% of total revenue in Q1, up from 60% in Q4 2025, signaling a structural shift from mobile to AI-driven growth.
- SemiTest revenue broke the $1 billion barrier for the first time, reaching $1.1 billion, with SoC at $882 million and memory at $203 million, driven by AI compute and HBM/DRAM demand.
- +7 more takeaways
ADP Q3 FY2026 Earnings Call - AI-Driven Efficiency Fuels Margin Expansion and Raised Guidance
ADP reported a strong Q3 FY2026, with revenue up 7%, adjusted EBIT margin expanding 80 basis points, and adjusted EPS growth of 10%, all beating expectations. The company raised its full-year guidance...
- Revenue grew 7% in Q3, with adjusted EBIT margin expanding 80 basis points and adjusted EPS rising 10%, all above internal expectations.
- Full-year guidance was raised across the board: revenue growth to 6-7%, adjusted EBIT margin expansion to 70-80 basis points, and adjusted EPS growth to 10-11%.
- AI-driven efficiency gains are materializing, with ADP Assist agents saving 30 minutes per payroll and reducing HR action clicks by 80%, contributing to an 8% YoY drop in small business client contacts.
- +7 more takeaways
GE HealthCare Q1 2026 Earnings Call - Inflationary Headwinds Force Profit Guidance Cut Despite Strong Top-Line Growth
GE HealthCare delivered top-line results at the high end of expectations, with $5.1 billion in revenue and 2.9% organic growth, but profit performance suffered from a $250 million inflationary shock. ...
- Revenue reached $5.1 billion, representing 2.9% organic growth year-over-year, landing at the high end of management's expectations.
- Full-year adjusted EPS guidance was reduced by $0.15 to a range of $4.80-$5.00, reflecting a prudent response to $250 million in inflationary cost pressures.
- Gross margin impact from inflation includes approximately $100 million in memory chip costs, $100 million in oil and freight increases, and $50 million in other commodities like tungsten.
- +7 more takeaways
Cognizant Q1 2026 Earnings Call - AI Builder Strategy Drives Record Bookings and Margin Expansion
Cognizant delivered a solid first quarter with revenue growth in the upper half of its guidance range, driven by strong performance in North America and the financial services segment. Bookings surged...
- Revenue grew 3.9% year-over-year in constant currency, landing in the upper half of the company's guidance range.
- Bookings surged 21% year-over-year, driven by seven large deals over $100 million and one mega deal exceeding $500 million.
- Adjusted operating margin expanded 10 basis points year-over-year to 15.6%, marking the fifth consecutive quarter of expansion.
- +7 more takeaways
Northern Oil and Gas Q1 2026 Earnings Call - Record Production Amidst Geopolitical Volatility and a $10B M&A Pipeline
Northern Oil and Gas delivered a record first quarter in 2026, pushing average daily production over 148,000 BOE per day. The company navigated significant macro turbulence, including a geopolitical c...
- Record Q1 2026 production averaged over 148,000 BOE per day, marking a 6% sequential increase and a new company high.
- A $521 million non-cash mark-to-market loss on derivatives was driven by a surge in oil prices due to the Iran conflict, though settled hedges only resulted in a $17.6 million loss.
- A $268 million non-cash impairment charge was recorded under the full-cost accounting method, but management indicated this is likely the last such charge for the year at current price levels.
- +7 more takeaways
Verisk Analytics Q1 2026 Earnings Call - Subscription Growth Resilience and AI Monetization Strategy
Verisk Analytics delivered a solid start to 2026 with organic constant currency revenue growth of 4.7%, driven by a resilient 7% jump in subscription revenues. Despite short-term headwinds like low we...
- Organic constant currency revenue grew 4.7%, beating management's internal expectations despite weather-related headwinds.
- Subscription revenues, representing 84% of total revenue, surged 7% on an organic constant currency basis, highlighting the mission-critical nature of the platform.
- Adjusted EBITDA margins expanded by 60 basis points to 55.9%, reflecting operational leverage and cost discipline offset by AI investments.
- +7 more takeaways
Orion Group Holdings Q1 2026 Earnings Call - Concrete Segment Surges on Data Center Boom
Orion Group Holdings delivered a solid start to 2026 with first-quarter revenue rising 15% year-over-year to $216 million, driven by a standout performance in its concrete segment. The concrete busine...
- Orion Group Holdings reported Q1 2026 revenue of $216 million, a 15% increase year-over-year, with GAAP net income of $4.7 million and adjusted EBITDA of $8.7 million.
- The concrete segment delivered a record quarter with $106 million in revenue and $8.6 million in adjusted EBITDA, a 73% margin expansion, driven by a 40% contribution from data center projects.
- The marine segment saw a temporary decline in adjusted EBITDA to $12 million from $17 million in Q1 2025, due to the winding down of large projects and early stages of new work.
- +9 more takeaways
Regeneron Pharmaceuticals Q1 2026 Earnings Call - Dupixent Drives Double-Digit Growth Amidst Pipeline Breakthroughs and Manufacturing Headwinds
Regeneron delivered a robust first quarter of 2026, posting 19% revenue growth and 15% non-GAAP EPS growth, anchored by a 31% jump in Dupixent sales to $4.9 billion. The immunology blockbuster continu...
- 1. Dupixent net sales surged 31% to $4.9 billion, reinforcing its status as the foundation of Regeneron’s immunology franchise with broad-based growth across indications and geographies.
- 2. Total revenues grew 19% year-over-year to $3.6 billion, while non-GAAP EPS increased 15% to $9.47, demonstrating strong operating leverage despite macroeconomic headwinds.
- 3. EYLEA HD U.S. net sales jumped 52% to $468 million, driven by physician adoption and label enhancements, though EYLEA legacy sales declined 36% due to conversion and competitive pressures.
- +17 more takeaways